Abacavir Dosing with Hepatic Dysfunction
Sir-We appreciate the topical review of antiretroviral drug pharmacokinetics in patients with hepatic dysfunction by Wyles and Gerber [1] . The authors note that alcohol dehydrogenase and glucuronyl transferase metabolize abacavir. Citing the absence of pharmacokinetic data from patients with liver disease, the authors recommend no change in the dose of abacavir for patients with hepatic dysfunction.
This recommendation, however, overlooks a previous study of abacavir pharmacokinetics in cirrhotic patients with mild hepatic impairment (defined as Child-Pugh scores of 5-6) [2] . In this study, the pharmacokinetics of single 600-mg doses of abacavir administered to 9 subjects with HIV infection who had received a diagnosis of moderate cirrhosis were compared with those of 9 controls who were matched for age, sex, and weight. In patients with mild hepatic dysfunction, the area under the concentration (AUC)-time curve increased by 89% and the half-life increased by 58%. In addition, the half-life of inactive metabolites increased by 21% to 31%. Although there were no adverse events after a single dose, the authors recommended a decrease of the abacavir dose to 150 mg twice per day. Similarly, the abacavir prescribing information specifies that a dose of 200 mg twice per day should be used in mild hepatic impairment and that abacavir is contraindicated in moderate to severe hepatic impairment [3] .
Finally, the association between alcohol dehydrogenase activity and liver disease is not certain in cases of nonalcoholic liver disease. It is relevant that in an open-label, randomized, 3-way crossover study of 25 HIV-infected subjects, ethanol induced an increase in the abacavir AUC of 41% and an increase in the elimination half-life of 26% [4] .
In summary, when used in patients with mild hepatic dysfunction in the presence of cirrhosis, a dose of 150-200 mg twice per day should be considered, especially for those who use alcohol. Abacavir should be avoided in those with more severe hepatic impairment. 
